26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies

Atopic dermatitis (AD) is a chronic, inflammatory skin disease. Patients’ quality of life is significantly impacted by pruritus leading to sleep disturbances. Ruxolitinib is a Janus kinase (JAK) 1/JAK2 inhibitor, and a cream formulation of ruxolitinib has demonstrated potent anti-inflammatory and antipruritic effects in patients with AD. Two phase 3 randomized studies (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment score of 2 or 3, and 3%–20% affected body surface area.